ZA200707639B - Methods of decreasing calcification - Google Patents

Methods of decreasing calcification

Info

Publication number
ZA200707639B
ZA200707639B ZA200707639A ZA200707639A ZA200707639B ZA 200707639 B ZA200707639 B ZA 200707639B ZA 200707639 A ZA200707639 A ZA 200707639A ZA 200707639 A ZA200707639 A ZA 200707639A ZA 200707639 B ZA200707639 B ZA 200707639B
Authority
ZA
South Africa
Prior art keywords
calcification
decreasing
methods
decreasing calcification
Prior art date
Application number
ZA200707639A
Other languages
English (en)
Inventor
Martin David
Portillo Juan Mariano
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA200707639B publication Critical patent/ZA200707639B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200707639A 2005-03-17 2007-09-05 Methods of decreasing calcification ZA200707639B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66327005P 2005-03-17 2005-03-17

Publications (1)

Publication Number Publication Date
ZA200707639B true ZA200707639B (en) 2008-06-25

Family

ID=36588866

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707639A ZA200707639B (en) 2005-03-17 2007-09-05 Methods of decreasing calcification

Country Status (15)

Country Link
US (1) US20060276534A1 (xx)
EP (1) EP1858553A2 (xx)
JP (1) JP2008533170A (xx)
KR (1) KR20070116817A (xx)
CN (1) CN101184508A (xx)
AU (1) AU2006227429A1 (xx)
BR (1) BRPI0609524A2 (xx)
CA (1) CA2601669A1 (xx)
CR (1) CR9439A (xx)
EA (1) EA200701995A1 (xx)
IL (1) IL185757A0 (xx)
MX (1) MX2007011153A (xx)
NO (1) NO20075304L (xx)
WO (1) WO2006102061A2 (xx)
ZA (1) ZA200707639B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007376A (ko) * 2005-05-23 2008-01-18 테바 파마슈티컬 인더스트리즈 리미티드 무정형 시나칼셋 염산염 및 이의 제조
AU2006304778B2 (en) * 2005-10-21 2011-04-28 Amgen Inc. Methods of decreasing vascular calcification using IL-1 inhibitors
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
EP2001832A1 (en) * 2006-03-23 2008-12-17 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CA2648939C (en) * 2006-04-20 2014-07-08 Amgen Inc. Stable emulsion formulations
CA2649616A1 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
KR20080011320A (ko) * 2006-04-27 2008-02-01 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
JP5671336B2 (ja) * 2007-05-08 2015-02-18 バーナム インスティテュート フォー メディカル リサーチ 組織非特異的アルカリホスファターゼ阻害因子および血管石灰化を処置するためのそれらの使用
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
CA3116635A1 (en) * 2018-10-25 2020-04-30 Opko Ireland Global Holdings, Ltd Methods of treatment with mixed metal compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE287390T1 (de) * 1994-10-21 2005-02-15 Nps Pharma Inc Kalzium-rezeptor aktive verbindungen
ATE430123T1 (de) * 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
US6362231B1 (en) * 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
CA2347092A1 (en) * 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
ATE286386T1 (de) * 1999-10-19 2005-01-15 Genzyme Corp Direktkomprimierter tablettenkern auf polymerbasis
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US20050288377A1 (en) * 2004-06-14 2005-12-29 Cantor Thomas L Use of calcimimetic as an adynamic bone disease related treatment

Also Published As

Publication number Publication date
AU2006227429A1 (en) 2006-09-28
WO2006102061A3 (en) 2006-12-14
IL185757A0 (en) 2008-01-06
JP2008533170A (ja) 2008-08-21
CR9439A (es) 2007-11-23
EA200701995A1 (ru) 2008-02-28
WO2006102061A2 (en) 2006-09-28
US20060276534A1 (en) 2006-12-07
BRPI0609524A2 (pt) 2011-10-18
MX2007011153A (es) 2007-12-12
KR20070116817A (ko) 2007-12-11
NO20075304L (no) 2007-11-29
EP1858553A2 (en) 2007-11-28
CN101184508A (zh) 2008-05-21
CA2601669A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
ZA200707639B (en) Methods of decreasing calcification
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
PL1931842T3 (pl) Zespół profili
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0525957D0 (en) Methods
GB0516068D0 (en) Well treatment
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
EP1890761A4 (en) PROCESS FOR REINFORCING LIPOLYSIS
GB0525540D0 (en) New treatment
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
GB0518232D0 (en) New methods
GB0502171D0 (en) Well treatment
GB0715741D0 (en) Methods
GB0518425D0 (en) Methods
GB0516204D0 (en) Methods
ZA200607681B (en) Treatment of water
GB0526212D0 (en) Methods
IL178683A0 (en) Methods of diminishing co-abuse potenitial
GB0514661D0 (en) Methods
GB0512574D0 (en) Uses of (s)-clenbuterol
IL166318A0 (en) Cortiutuo shape of sigu
GB0510013D0 (en) Interaction of SNEV
AU306395S (en) Shower
AU306394S (en) Shower
GB0518003D0 (en) Treatment of hepatatis c